GRAIL
Over half of employers’ skyrocketing cancer costs are driven by treatment for late-stage disease, when 5-year survival is just 21%. The Galleri test, which screens for a signal shared by more than 50 cancers, was found to potentially detect up to 98% of diagnosed cancer types in a typical employer population.
The Galleri test is a comprehensive experience, including:
-Telemedicine services, including eligibility verification and results reporting
-Test kit, shipment and blood draw facilitation at home, lab or onsite
-Expert peer-to-peer physician support
-1:1 patient advocacy services
Programs:
Cancer CareBiometric Screening
